Acute hepatic porphyria (AHP) is comprised of four subtypes, each resulting from a genetic defect leading to deficiency in one of the enzymes of the heme biosynthesis pathway in the liver: acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and ALAD-deficiency porphyria (ADP).
AHP refers to a family of rare, genetic diseases characterized by potentially life-threatening attacks and, for many patients, chronic debilitating symptoms that negatively impact daily functioning and quality of life.
Common symptoms include severe, diffuse abdominal pain, weakness, nausea, and fatigue.
HCP and VP are classified as acute but can also have symptoms that affect the skin—specifically blistering skin lesions on sun-exposed areas. Skin symptoms can be present with or without attacks.
HCPs: Want more information about AHP to share with your patients? Start Here
While Alnylam provides financial support for this program, all tests and services are performed by independent third parties. Healthcare professionals must confirm that the patients meet certain criteria to use the program. Alnylam receives de-identified patient data from this program, but at no time does Alnylam receive patient-identifiable information. Alnylam receives contact information for healthcare professionals who use this program.
Download the Alnyam Act® Brochures for Acute Hepatic Porphyria